YD Bio (YDES) Total Liabilities (2024 - 2025)
YD Bio (YDES) posted quarterly Total Liabilities of $16.6 million for Q4 2025, up 5971.63% year-over-year from $273980.0 in Q4 2024, and up 2109.36% quarter-over-quarter from $752935.0 in Q2 2025.
YD Bio (YDES) Total Liabilities (2024 - 2025) Analysis & Trends
YD Bio (YDES) has reported Total Liabilities for 2 consecutive years, with $16.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities rose 5971.63% year-over-year to $16.6 million; the TTM figure through Dec 2025 stood at $16.6 million (up 5971.63% YoY), while the FY2025 annual figure was $16.6 million, up 5971.63% from the prior year.
- Total Liabilities climbed to $16.6 million in Q4 2025 per YDES's latest filing, from $752935.0 in the prior quarter.
- Across five years, Total Liabilities topped out at $16.6 million in Q4 2025 and bottomed at $273980.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 10.03 Bn |
| 10 | YD Bio | 311.58 Mn | 305.57 Mn | - | 16.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.64 Mn |
| Jun 30, 2025 | 752,935.00 |
| Dec 31, 2024 | 273,980.00 |